-- DBMS: bigquery
CREATE TABLE `isb-cgc-bq.HTAN_versioned.clinical_tier1_diagnosis_r3`
(
  Component STRING OPTIONS(description="Category of metadata (e.g. Diagnosis, Biospecimen, scRNA-seq Level 1, etc.); provide the same one for all items/rows."),
  HTAN_Participant_ID STRING OPTIONS(description="HTAN ID associated with a patient based on HTAN ID SOP (eg HTANx_yyy )"),
  Age_at_Diagnosis STRING OPTIONS(description="Age at the time of diagnosis expressed in number of days since birth."),
  Year_of_Diagnosis STRING OPTIONS(description="Numeric value to represent the year of an individual's initial pathologic diagnosis of cancer."),
  Primary_Diagnosis STRING OPTIONS(description="Text term used to describe the patient's histologic diagnosis, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Site_of_Resection_or_Biopsy STRING OPTIONS(description="The text term used to describe the anatomic site of origin, of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Tissue_or_Organ_of_Origin STRING OPTIONS(description="The text term used to describe the anatomic site of origin, of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O)."),
  Morphology STRING OPTIONS(description="The third edition of the International Classification of Diseases for Oncology, published in 2000 used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms. The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs. In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains. A system of numbered categories for representation of data."),
  Tumor_Grade STRING OPTIONS(description="Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness."),
  Progression_or_Recurrence STRING OPTIONS(description="Yes/No/unknown indicator to identify whether a patient has had a new tumor event after initial treatment."),
  Last_Known_Disease_Status STRING OPTIONS(description="Text term that describes the last known state or condition of an individual's neoplasm."),
  Days_to_Last_Follow_up STRING OPTIONS(description="Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days. If not applicable please enter 'Not Applicable'"),
  Days_to_Last_Known_Disease_Status STRING OPTIONS(description="Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days. If not applicable please enter 'Not Applicable'"),
  Method_of_Diagnosis STRING OPTIONS(description="Text term used to describe the method used to confirm the patients malignant diagnosis."),
  Prior_Malignancy STRING OPTIONS(description="The yes/no/unknown indicator used to describe the patient's history of prior cancer diagnosis."),
  Prior_Treatment STRING OPTIONS(description="A yes/no/unknown/not applicable indicator related to the administration of therapeutic agents received before the body specimen was collected."),
  Metastasis_at_Diagnosis STRING OPTIONS(description="The text term used to describe the extent of metastatic disease present at diagnosis."),
  Metastasis_at_Diagnosis_Site STRING OPTIONS(description="Text term to identify an anatomic site in which metastatic disease involvement is found."),
  First_Symptom_Prior_to_Diagnosis STRING OPTIONS(description="Text term used to describe the patient's first symptom experienced prior to diagnosis and thought to be related to the disease."),
  Days_to_Diagnosis STRING OPTIONS(description="Number of days between the date used for index and the date the patient was diagnosed with the malignant disease. If not applicable please enter 'Not Applicable'"),
  Percent_Tumor_Invasion STRING OPTIONS(description="The percentage of tumor cells spread locally in a malignant neoplasm through infiltration or destruction of adjacent tissue."),
  Residual_Disease STRING OPTIONS(description="Text terms to describe the status of a tissue margin following surgical resection."),
  Synchronous_Malignancy STRING OPTIONS(description="A yes/no/unknown indicator used to describe whether the patient had an additional malignant diagnosis at the same time the tumor used for sequencing was diagnosed. If both tumors were sequenced, both tumors would have synchronous malignancies."),
  Tumor_Confined_to_Organ_of_Origin STRING OPTIONS(description="The yes/no/unknown indicator used to describe whether the tumor is confined to the organ where it originated and did not spread to a proximal or distant location within the body."),
  Tumor_Focality STRING OPTIONS(description="The text term used to describe whether the patient's disease originated in a single location or multiple locations."),
  Tumor_Largest_Dimension_Diameter STRING OPTIONS(description="Numeric value used to describe the maximum diameter or dimension of the primary tumor, measured in centimeters."),
  Gross_Tumor_Weight STRING OPTIONS(description="Numeric value used to describe the gross pathologic tumor weight, measured in grams."),
  Breslow_Thickness STRING OPTIONS(description="The number that describes the distance, in millimeters, between the upper layer of the epidermis and the deepest point of tumor penetration."),
  Vascular_Invasion_Present STRING OPTIONS(description="The yes/no indicator to ask if large vessel or venous invasion was detected by surgery or presence in a tumor specimen."),
  Vascular_Invasion_Type STRING OPTIONS(description="Text term that represents the type of vascular tumor invasion."),
  Anaplasia_Present STRING OPTIONS(description="Yes/no/unknown/Not Reported indicator used to describe whether anaplasia was present at the time of diagnosis."),
  Anaplasia_Present_Type STRING OPTIONS(description="The text term used to describe the morphologic findings indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample."),
  Laterality STRING OPTIONS(description="For tumors in paired organs, designates the side on which the cancer originates."),
  Perineural_Invasion_Present STRING OPTIONS(description="A yes/no indicator to ask if perineural invasion or infiltration of tumor or cancer is present."),
  Lymphatic_Invasion_Present STRING OPTIONS(description="A yes/no indicator to ask if small or thin-walled vessel invasion is present, indicating lymphatic involvement"),
  Lymph_Nodes_Positive STRING OPTIONS(description="The number of lymph nodes involved with disease as determined by pathologic examination."),
  Lymph_Nodes_Tested STRING OPTIONS(description="The number of lymph nodes tested to determine whether lymph nodes were involved with disease as determined by a pathologic examination."),
  Peritoneal_Fluid_Cytological_Status STRING OPTIONS(description="The text term used to describe the malignant status of the peritoneal fluid determined by cytologic testing."),
  Classification_of_Tumor STRING OPTIONS(description="Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint."),
  Best_Overall_Response STRING OPTIONS(description="The best improvement achieved throughout the entire course of protocol treatment."),
  Mitotic_Count STRING OPTIONS(description="The number of mitoses identified under the microscope in tumors. The method of counting varies, according to the specific tumor examined. Usually, the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields."),
  AJCC_Clinical_M STRING OPTIONS(description="Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  AJCC_Clinical_N STRING OPTIONS(description="Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  AJCC_Clinical_Stage STRING OPTIONS(description="Stage group determined from clinical information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for cancer."),
  AJCC_Clinical_T STRING OPTIONS(description="Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment."),
  AJCC_Pathologic_M STRING OPTIONS(description="Code to represent the defined absence or presence of distant spread or metastases (M) to locations via vascular channels or lymphatics beyond the regional lymph nodes, using criteria established by the American Joint Committee on Cancer (AJCC)."),
  AJCC_Pathologic_N STRING OPTIONS(description="The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."),
  AJCC_Pathologic_Stage STRING OPTIONS(description="The extent of a cancer, especially whether the disease has spread from the original site to other parts of the body based on AJCC staging criteria."),
  AJCC_Pathologic_T STRING OPTIONS(description="Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC)."),
  AJCC_Staging_System_Edition STRING OPTIONS(description="The text term used to describe the version or edition of the American Joint Committee on Cancer Staging Handbooks, a publication by the group formed for the purpose of developing a system of staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications."),
  Cog_Neuroblastoma_Risk_Group STRING OPTIONS(description="Text term that represents the categorization of patients on the basis of prognostic factors per a system developed by Children's Oncology Group (COG). Risk level is used to assign treatment intensity."),
  Cog_Rhabdomyosarcoma_Risk_Group STRING OPTIONS(description="Text term used to describe the classification of rhabdomyosarcoma, as defined by the Children's Oncology Group (COG)."),
  Gleason_Grade_Group STRING OPTIONS(description="The text term used to describe the overall grouping of grades defined by the Gleason grading classification, which is used to determine the aggressiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  Gleason_Grade_Tertiary STRING OPTIONS(description="The text term used to describe the tertiary pattern as described by the Gleason Grading System."),
  Gleason_Patterns_Percent STRING OPTIONS(description="Numeric value that represents the percentage of Patterns 4 and 5, which is used when the Gleason score is greater than 7 to predict prognosis."),
  Greatest_Tumor_Dimension STRING OPTIONS(description="Numeric value that represents the measurement of the widest portion of the tumor in centimeters."),
  IGCCCG_Stage STRING OPTIONS(description="The text term used to describe the International Germ Cell Cancer Collaborative Group (IGCCCG), a grouping used to further classify metastatic testicular tumors."),
  INPC_Grade STRING OPTIONS(description="Text term used to describe the classification of neuroblastic differentiation within neuroblastoma tumors, as defined by the International Neuroblastoma Pathology Classification (INPC)."),
  INPC_Histologic_Group STRING OPTIONS(description="The text term used to describe the classification of neuroblastomas distinguishing between favorable and unfavorable histologic groups. The histologic score, defined by the International Neuroblastoma Pathology Classification (INPC), is based on age, mitosis-karyorrhexis index (MKI), stromal content and degree of tumor cell differentiation."),
  INRG_Stage STRING OPTIONS(description="The text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Risk Group (INRG)."),
  INSS_Stage STRING OPTIONS(description="Text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Staging System (INSS)."),
  International_Prognostic_Index STRING OPTIONS(description="The text term used to describe the International Prognostic Index, which classifies the prognosis of patients with aggressive non-Hodgkin's lymphoma."),
  IRS_Group STRING OPTIONS(description="Text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS)."),
  IRS_Stage STRING OPTIONS(description="The text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS)."),
  ISS_Stage STRING OPTIONS(description="The multiple myeloma disease stage at diagnosis."),
  Lymph_Node_Involved_Site STRING OPTIONS(description="The text term used to describe the anatomic site of lymph node involvement."),
  Margin_Distance STRING OPTIONS(description="Numeric value (in centimeters) that represents the distance between the tumor and the surgical margin."),
  Margins_Involved_Site STRING OPTIONS(description="The text term used to describe the anatomic sites that were involved in the survival margins."),
  Medulloblastoma_Molecular_Classification STRING OPTIONS(description="The text term used to describe the classification of medulloblastoma tumors based on molecular features."),
  Micropapillary_Features STRING OPTIONS(description="The yes/no/unknown indicator used to describe whether micropapillary features were determined to be present."),
  Mitosis_Karyorrhexis_Index STRING OPTIONS(description="Text term that represents the component of the International Neuroblastoma Pathology Classification (INPC) for mitosis-karyorrhexis index (MKI)."),
  Non_Nodal_Regional_Disease STRING OPTIONS(description="The text term used to describe whether the patient had non-nodal regional disease."),
  Non_Nodal_Tumor_Deposits STRING OPTIONS(description="The yes/no/unknown indicator used to describe the presence of tumor deposits in the pericolic or perirectal fat or in adjacent mesentery away from the leading edge of the tumor."),
  Ovarian_Specimen_Status STRING OPTIONS(description="The text term used to describe the physical condition of the involved ovary."),
  Ovarian_Surface_Involvement STRING OPTIONS(description="The text term that describes whether the surface tissue (outer boundary) of the ovary shows evidence of involvement or presence of cancer."),
  Pregnant_at_Diagnosis STRING OPTIONS(description="The text term used to indicate whether the patient was pregnant at the time they were diagnosed."),
  Primary_Gleason_Grade STRING OPTIONS(description="The text term used to describe the primary Gleason score, which describes the pattern of cells making up the largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  Secondary_Gleason_Grade STRING OPTIONS(description="The text term used to describe the secondary Gleason score, which describes the pattern of cells making up the second largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing."),
  Supratentorial_Localization STRING OPTIONS(description="Text term to specify the location of the supratentorial tumor."),
  Tumor_Depth STRING OPTIONS(description="Numeric value that represents the depth of tumor invasion, measured in millimeters (mm)."),
  WHO_CNS_Grade STRING OPTIONS(description="WHO CNS Grade"),
  WHO_NTE_Grade STRING OPTIONS(description="WHO NTE Grade"),
  Days_to_Progression STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease progressed. If not applicable please enter 'Not Applicable'"),
  Days_to_Progression_Free STRING OPTIONS(description="Number of days between the date used for index and the date the patient's disease was formally confirmed as progression-free. If not applicable please enter 'Not Applicable'"),
  NCI_Atlas_Cancer_Site STRING OPTIONS(description="The primary tumor site used to calculate the incidence rate using the NCI Cancer Atlas, a digital atlas which provides geographical data related to cancer utilizing the Surveillance, Epidemiology, and End Results (SEER) Program cancer incidence rates for 2013 to 2017"),
  Progression_or_Recurrence_Type STRING OPTIONS(description="The text term used to describe the type of progressive or recurrent disease or relapsed disease."),
  Sentinel_Lymph_Node_Count STRING OPTIONS(description="Numeric count of sentinel lymph nodes."),
  Sentinel_Node_Positive_Assessment_Count STRING OPTIONS(description="The number or amount of metastatic neoplasms related to the confirmed presence of disease or specific microorganisms during examination of the first rounded mass of lymphatic tissue to which cancer is likely to spread from the primary tumor."),
  Tumor_Extranodal_Extension_Indicator STRING OPTIONS(description="The indicator to determine extranodal involvement or extent of the disease."),
  Satellite_Metastasis_Present_Indicator STRING OPTIONS(description="A yes/no indicator to ask if intransit metastases or satellite lesions are present."),
  Other_Biopsy_Resection_Site STRING OPTIONS(description="A description of the location on or within the human body where the surgical biopsy/resection procedure was performed (Not covered under HTAN Clinical Data Tier 1)"),
  Extent_of_Tumor_Resection STRING OPTIONS(description="The degree to which the lesion has been cut out, or resected."),
  Precancerous_Condition_Type STRING OPTIONS(description="The classification of pre-cancerous cells found in a specific collection of data being studied by the Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions (MCL)."),
  Mode_of_Cancer_Detection STRING OPTIONS(description="Text term used to describe the mode of cancer detection, like standard of care screening or random detection"),
  Topography_Code STRING OPTIONS(description="Topography Code, indicating site within the body, based on ICD-O-3."),
  Additional_Topography STRING OPTIONS(description="Topography not included in the ICD-O-3 Topography codes."),
  entityId STRING OPTIONS(description="Synapse ID of entity"),
  HTAN_Center STRING OPTIONS(description="Name of HTAN Center e.g. HTAN HTAPP"),
  Data_Release STRING OPTIONS(description="Inclusion in HTAN Data Release e.g. Release 1.0"),
  Manifest_Version INT64 OPTIONS(description="Latest version of metadata manifest"),
  Uuid STRING OPTIONS(description="Unique identifier of entity e.g. a96059eb-81af-4b24-ae50-9242c0d8f819")
)
OPTIONS(
  friendly_name="HTAN CLINICAL TIER 1 DATA - DIAGNOSIS R3 VERSIONED",
  description="This table contains diagnostic clinical information about HTAN patient cases based on the NCI Genomic Data Commons (GDC) clinical data model. Data was extracted from HTAN Synapse projects in April 2023. More details: see https://data.humantumoratlas.org/standard/clinical",
  labels=[("access", "open"), ("data_type", "clinical_data"), ("program", "htan"), ("source", "htan"), ("category", "clinical_biospecimen_data"), ("status", "current")]
);

INSERT INTO `isb-cgc-bq.HTAN_versioned.clinical_tier1_diagnosis_r3` (Component, HTAN_Participant_ID, Age_at_Diagnosis, Year_of_Diagnosis, Primary_Diagnosis, Site_of_Resection_or_Biopsy, Tissue_or_Organ_of_Origin, Morphology, Tumor_Grade, Progression_or_Recurrence, Last_Known_Disease_Status, Days_to_Last_Follow_up, Days_to_Last_Known_Disease_Status, Method_of_Diagnosis, Prior_Malignancy, Prior_Treatment, Metastasis_at_Diagnosis, Metastasis_at_Diagnosis_Site, First_Symptom_Prior_to_Diagnosis, Days_to_Diagnosis, Percent_Tumor_Invasion, Residual_Disease, Synchronous_Malignancy, Tumor_Confined_to_Organ_of_Origin, Tumor_Focality, Tumor_Largest_Dimension_Diameter, Gross_Tumor_Weight, Breslow_Thickness, Vascular_Invasion_Present, Vascular_Invasion_Type, Anaplasia_Present, Anaplasia_Present_Type, Laterality, Perineural_Invasion_Present, Lymphatic_Invasion_Present, Lymph_Nodes_Positive, Lymph_Nodes_Tested, Peritoneal_Fluid_Cytological_Status, Classification_of_Tumor, Best_Overall_Response, Mitotic_Count, AJCC_Clinical_M, AJCC_Clinical_N, AJCC_Clinical_Stage, AJCC_Clinical_T, AJCC_Pathologic_M, AJCC_Pathologic_N, AJCC_Pathologic_Stage, AJCC_Pathologic_T, AJCC_Staging_System_Edition, Cog_Neuroblastoma_Risk_Group, Cog_Rhabdomyosarcoma_Risk_Group, Gleason_Grade_Group, Gleason_Grade_Tertiary, Gleason_Patterns_Percent, Greatest_Tumor_Dimension, IGCCCG_Stage, INPC_Grade, INPC_Histologic_Group, INRG_Stage, INSS_Stage, International_Prognostic_Index, IRS_Group, IRS_Stage, ISS_Stage, Lymph_Node_Involved_Site, Margin_Distance, Margins_Involved_Site, Medulloblastoma_Molecular_Classification, Micropapillary_Features, Mitosis_Karyorrhexis_Index, Non_Nodal_Regional_Disease, Non_Nodal_Tumor_Deposits, Ovarian_Specimen_Status, Ovarian_Surface_Involvement, Pregnant_at_Diagnosis, Primary_Gleason_Grade, Secondary_Gleason_Grade, Supratentorial_Localization, Tumor_Depth, WHO_CNS_Grade, WHO_NTE_Grade, Days_to_Progression, Days_to_Progression_Free, NCI_Atlas_Cancer_Site, Progression_or_Recurrence_Type, Sentinel_Lymph_Node_Count, Sentinel_Node_Positive_Assessment_Count, Tumor_Extranodal_Extension_Indicator, Satellite_Metastasis_Present_Indicator, Other_Biopsy_Resection_Site, Extent_of_Tumor_Resection, Precancerous_Condition_Type, Mode_of_Cancer_Detection, Topography_Code, Additional_Topography, entityId, HTAN_Center, Data_Release, Manifest_Version, Uuid) VALUES ('Diagnosis', 'HTA3_8001', '26310', '2018', 'Adenocarcinoma NOS', 'Lower lobe lung', 'Lung NOS', '8140/3', 'G2', 'No', 'Tumor free', '0', '0', NULL, 'Yes', 'Yes', 'No Metastasis', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Right', NULL, NULL, '0', '5', 'Not Reported', NULL, NULL, NULL, 'M0', 'N0', 'Stage IA2', 'T1b', 'M0', 'N0', 'Stage IA2', 'T1b', '8th', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'syn24994547', 'HTAN BU', 'Release 1.0', 2, '7025a134-99d1-4fa0-8884-a742f28e349b'), ('Diagnosis', 'HTA3_8002', '27294', '2018', 'Adenocarcinoma NOS', 'Upper lobe lung', 'Lung NOS', '8140/3', 'G2', 'No', 'Tumor free', '0', '0', NULL, 'Yes', 'Yes', 'No Metastasis', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Left', NULL, NULL, '0', '13', 'Not Reported', NULL, NULL, NULL, 'M0', 'N0', 'Stage IA2', 'T1b', 'M0', 'N0', 'Stage IA2', 'T1b', '8th', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'syn24994548', 'HTAN BU', 'Release 1.0', 2, '896b742f-98c7-49df-a328-4268e488e607'), ('Diagnosis', 'HTA3_8003', '28130', '2019', 'Adenocarcinoma NOS', 'Upper lobe lung', 'Lung NOS', '8140/3', 'G2', 'No', 'Tumor free', '0', '0', NULL, 'No', 'No', 'No Metastasis', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Right', NULL, NULL, '0', '5', 'Not Reported', NULL, NULL, NULL, 'M0', 'N0', NULL, 'T1c', 'M0', 'N0', NULL, 'T1c', '8th', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'syn24994549', 'HTAN BU', 'Release 1.0', 2, 'f4667a1a-0132-4afa-9a7f-cb5775b0a3cc'), ('Diagnosis', 'HTA3_8004', '27939', '2019', 'Adenocarcinoma NOS', 'Lower lobe lung', 'Lung NOS', '8140/3', 'G2', 'No', 'Tumor free', '0', '0', NULL, 'No', 'No', 'No Metastasis', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Right', NULL, NULL, '1', '5', 'Not Reported', NULL, NULL, NULL, 'M0', 'N1', 'Stage IIB', 'T1b', 'M0', 'N1', 'Stage IIB', 'T1b', '8th', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'syn24994550', 'HTAN BU', 'Release 1.0', 2, 'ea4b2524-56b2-4afc-8289-5cc832302e30'), ('Diagnosis', 'HTA3_8005', '24818', '2019', 'Adenocarcinoma NOS', 'Upper lobe lung', 'Lung NOS', '8140/3', 'G1', 'No', 'Tumor free', '0', '0', NULL, 'No', 'No', 'No Metastasis', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Left', NULL, NULL, '0', '7', 'Not Reported', NULL, NULL, NULL, 'M0', 'N0', 'Stage IA1', 'T1mi', 'M0', 'N0', 'Stage IA1', 'T1mi', '8th', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'syn24994551', 'HTAN BU', 'Release 1.0', 2, 'fbf340bc-71c0-4e2c-89a9-80258aed5855');